Sequencing Structural Variants in Cancer for Precision Therapeutics

Area of Science:

• Oncology
• Genomics
• Molecular Diagnostics

Background:

• Cancer therapy selection increasingly relies on identifying specific mutations.
• Current solid tumor profiling primarily uses DNA sequencing for point mutations.
• Many aggressive cancers are driven by structural variants missed by standard assays.

Purpose of the Study:

• To address the unmet need for clinical assays that can rapidly and affordably profile structural variants in solid tumors.
• To review the landscape of actionable structural variants in cancer.
• To identify promising detection strategies for structural variants using massively-parallel sequencing.

Main Methods:

• Literature review of current cancer profiling techniques.
• Survey of 'actionable' structural variants in various cancers.
• Evaluation of massively-parallel sequencing strategies for variant detection.

Main Results:

• Standard DNA sequencing assays often fail to detect critical structural variants.
• Specific cancers like ovarian, oesophageal, and small-cell lung cancer are driven by these variants.
• Massively-parallel sequencing offers promising avenues for structural variant detection.

Conclusions:

• There is a significant clinical need for improved methods to detect structural variants in solid tumors.
• Actionable structural variants represent a key area for therapeutic targeting.
• Advancements in massively-parallel sequencing are vital for developing effective clinical assays.